HDLForum

What's New

• HDL cholesterol: a prognostic marker in idiopathic pulmonary arterial hypertension?
• CETP inhibition after dalcetrapib? A perspective from the HDL Forum Editors
• RVX-208: first in class epigenetic mode of action in targeting apolipoprotein A-I
• Dalcetrapib trial DAL-VESSEL published in European Heart Journal
• Niacin and diabetes control
• Post-ASSERT: Ongoing trials with RVX-208

Viewpoints

Expert Opinion: Focus on HDL

Professor John Chapman, INSERM, Paris, France and President of the European Atherosclerosis Society reviews evidence for HDL as a potential therapeutic target, with a focus on clinical trial for established treatments.

• Do statins raise HDL-C levels? And if so, how?

Watch the video here

Hot Topic

Managing dyslipidemic patients with the metabolic syndrome - Focus on the HDL-triglyceride axis
A roundtable discussion for HDL Forum held during the European Atherosclerosis Society Congress, 26-29th June, 2011 Gothenburg, Sweden

Outcomes studies with CETP inhibitors - hypothetical discussions

Professor Philip Barter, HDL Forum Editor and Director of The Heart Research Institute, Sydney Australia

Forthcoming Meetings

13-16 March, 2012: 4th International Singapore Lipid Symposium (ISLS)
Singapore
More Information

24-27 March, 2012: ACC12
Chicago, USA
More Information

25-29 March, 2012: XVI International Symposium on Atherosclerosis (ISA2012)
Sydney, Australia
More Information

30 March-1 April 2012: HDL Satellite Symposium 2012
Cairns, Tropical North Queensland, Australia
More Information

18-20 April, 2012: ATVB 2012
Chicago, USA
More Information